Non-Small Cell Lung Cancer Cells Expressing CD44 Are Enriched for Stem Cell-Like Properties

Background The cancer stem cell theory hypothesizes that cancers are perpetuated by cancer stem cells (CSC) or tumor initiating cells (TIC) possessing self-renewal and other stem cell-like properties while differentiated non-stem/initiating cells have a finite life span. To investigate whether the hypothesis is applicable to lung cancer, identification of lung CSC and demonstration of these capacities is essential. Methodology/Principal Finding The expression profiles of five stem cell markers (CD34, CD44, CD133, BMI1 and OCT4) were screened by flow cytometry in 10 lung cancer cell lines. CD44 was further investigated by testing for in vitro and in vivo tumorigenecity. Formation of spheroid bodies and in vivo tumor initiation ability were demonstrated in CD44+ cells of 4 cell lines. Serial in vivo tumor transplantability in nude mice was demonstrated using H1299 cell line. The primary xenografts initiated from CD44+ cells consisted of mixed CD44+ and CD44− cells in similar ratio as the parental H1299 cell line, supporting in vivo differentiation. Semi-quantitative Real-Time PCR (RT-PCR) showed that both freshly sorted CD44+ and CD44+ cells derived from CD44+-initiated tumors expressed the pluripotency genes OCT4/POU5F1, NANOG, SOX2. These stemness markers were not expressed by CD44− cells. Furthermore, freshly sorted CD44+ cells were more resistant to cisplatin treatment with lower apoptosis levels than CD44− cells. Immunohistochemical analysis of 141 resected non-small cell lung cancers showed tumor cell expression of CD44 in 50.4% of tumors while no CD34, and CD133 expression was observed in tumor cells. CD44 expression was associated with squamous cell carcinoma but unexpectedly, a longer survival was observed in CD44-expressing adenocarcinomas. Conclusion/Significance Overall, our results demonstrated that stem cell-like properties are enriched in CD44-expressing subpopulations of some lung cancer cell lines. Further investigation is required to clarify the role of CD44 in tumor cell renewal and cancer propagation in the in vivo environment.

[1]  Li Chai,et al.  Sall4 modulates embryonic stem cell pluripotency and early embryonic development by the transcriptional regulation of Pou5f1 , 2006, Nature Cell Biology.

[2]  L. Herzenberg,et al.  Modern flow cytometry: a practical approach. , 2007, Clinics in laboratory medicine.

[3]  Shulan Tian,et al.  Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells , 2007, Science.

[4]  Ian A. White,et al.  CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. , 2008, The Journal of clinical investigation.

[5]  Marcos J. Araúzo-Bravo,et al.  Oct4-Induced Pluripotency in Adult Neural Stem Cells , 2009, Cell.

[6]  G. Viglietto,et al.  The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. , 2009, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[7]  J. Jagirdar,et al.  CD44 and its v6 spliced variant in lung tumors , 1997, Cancer.

[8]  I. Takanami,et al.  Expression and prognostic value of the standard CD44 protein in pulmonary adenocarcinoma. , 2000, Oncology reports.

[9]  D. Lai,et al.  Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3. , 2010, Acta biochimica et biophysica Sinica.

[10]  J. Sleeman,et al.  CD44 is required for two consecutive steps in HGF/c-Met signaling. , 2002, Genes & development.

[11]  L. Fink,et al.  Generation and characterization of functional cardiomyocytes using induced pluripotent stem cells derived from human fibroblasts , 2009, Cell biology international.

[12]  F. Gage,et al.  Setting Standards for Human Embryonic Stem Cells , 2003, Science.

[13]  A. Puisieux,et al.  Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition , 2008, PloS one.

[14]  J. Dick.  Future prospects for animal models created by transplanting human haematopoietic cells into immune-deficient mice. , 1994, Research in immunology.

[15]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[16]  Stephen Lam,et al.  Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. , 2007, Cancer research.

[17]  T. Jacks,et al.  Identification of Bronchioalveolar Stem Cells in Normal Lung and Lung Cancer , 2005, Cell.

[18]  E. Hurt,et al.  CD44+CD24− prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis , 2008, British Journal of Cancer.

[19]  R. Bajpai,et al.  Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines. , 2008, Cancer research.

[20]  F. Bertucci,et al.  Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. , 2009, Cancer research.

[21]  Yaojiong Wu,et al.  CD133 as a marker for cancer stem cells: progresses and concerns. , 2009, Stem cells and development.

[22]  M. Asadi-lari,et al.  CD44+ cancer cells express higher levels of the anti-apoptotic protein Bcl-2 in breast tumours. , 2009, Cancer immunity.

[23]  Peter Dirks,et al.  Separating stem cells by flow cytometry: reducing variability for solid tissues. , 2009, Cell stem cell.

[24]  D. Scudiero,et al.  Complex Display of Putative Tumor Stem Cell Markers in the NCI60 Tumor Cell Line Panel , 2010, Stem cells.

[25]  G. Dontu,et al.  Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. , 2006, Cancer research.

[26]  S. Morrison,et al.  Efficient tumor formation by single human melanoma cells , 2008, Nature.

[27]  M. Slomiany,et al.  Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. , 2008, Seminars in cancer biology.

[28]  L. Ricci-Vitiani,et al.  Identification and expansion of human colon-cancer-initiating cells , 2007, Nature.

[29]  J. Minna,et al.  Distinct Epidermal Growth Factor Receptor and KRAS Mutation Patterns in Non–Small Cell Lung Cancer Patients with Different Tobacco Exposure and Clinicopathologic Features , 2006, Clinical Cancer Research.

[30]  Anna E. Lokshin,et al.  Drug-Selected Human Lung Cancer Stem Cells: Cytokine Network, Tumorigenic and Metastatic Properties , 2008, PloS one.

[31]  L. Mariani,et al.  Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment , 2009, Proceedings of the National Academy of Sciences.

[32]  E. Verwiel,et al.  Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis. , 2008, Cancer research.

[33]  Danila Coradini,et al.  Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. , 2005, Cancer research.

[34]  I. Ng,et al.  Identification and characterization of tumorigenic liver cancer stem/progenitor cells. , 2007, Gastroenterology.

[35]  Yuh-Lih Chang,et al.  Oct-4 Expression Maintained Cancer Stem-Like Properties in Lung Cancer-Derived CD133-Positive Cells , 2008, PloS one.

[36]  K. Konstantopoulos,et al.  Selectin Ligand Expression Regulates the Initial Vascular Interactions of Colon Carcinoma Cells , 2006, Journal of Biological Chemistry.

[37]  E. Srivatsan,et al.  The Malignant Pleural Effusion as a Model to Investigate Intratumoral Heterogeneity in Lung Cancer , 2009, PloS one.

[38]  K. Mimori,et al.  CD133+CD44+ Population Efficiently Enriches Colon Cancer Initiating Cells , 2008, Annals of Surgical Oncology.

[39]  X. Yang,et al.  Expression of CD44 in human lung tumors. , 1994, Cancer research.

[40]  E. Scott,et al.  Aldehyde dehydrogenase activity as a functional marker for lung cancer. , 2009, Chemico-biological interactions.

[41]  Feng Jiang,et al.  Aldehyde Dehydrogenase 1 Is a Tumor Stem Cell-Associated Marker in Lung Cancer , 2009, Molecular Cancer Research.

[42]  J. Minna,et al.  Establishment and Expression Profiling of New Lung Cancer Cell Lines from Chinese Smokers and Lifetime Never-Smokers , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[43]  M. Biffoni,et al.  Identification and expansion of the tumorigenic lung cancer stem cell population , 2008, Cell Death and Differentiation.

[44]  M. Slomiany,et al.  Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[45]  Lei Du,et al.  CD44 is of Functional Importance for Colorectal Cancer Stem Cells , 2008, Clinical Cancer Research.

[46]  L. Bourguignon,et al.  Heregulin-mediated ErbB2-ERK Signaling Activates Hyaluronan Synthases Leading to CD44-dependent Ovarian Tumor Cell Growth and Migration* , 2007, Journal of Biological Chemistry.

[47]  I. Nazarenko,et al.  CD44 and EpCAM: cancer-initiating cell markers. , 2008, Current molecular medicine.

[48]  C. Shih,et al.  Identification of uPAR-positive Chemoresistant Cells in Small Cell Lung Cancer , 2007, PloS one.